About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Level of HER2-neu Gene Amplification an Response to Trastuzumab

NCT00874146·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Armando Santoro, MD
CONTACT
++39-028224 armando.santoro@humanitas.it
Giuseppe Gullo, MD
CONTACT
++39-028224 giuseppe.gullo@humanitas.it

Lead

Istituto Clinico Humanitas

Age

18–any

Sex

FEMALE

Healthy volunteers

Not accepted

You may be eligible if

HER2-positive breast cancer Trastuzumab-containing regimen delivered for advanced disease Tumor sample available at Pathology Archive

You may not be if

HER2-negative advanced breast cancer Pretreatment with trastuzumab

The record

StatusUnknown

PhaseNo phase

Taking part100

StartedMar 2009

UpdatedSep 2, 2010

Conditions

Advanced Breast Cancer

Where1

Istituto Clinco Humanitas
Rozzano, Milan, Italy

Clareo Health | Level of HER2-neu Gene Amplification an Response to Trastuzumab